Kaplan-Meier survival analysis indicated that higher expression of GPC2 predicted worse clinical outcome in patients with prostate cancer, suggesting a potential role of GPC2 in prognostic prediction in prostate cancer. The gene discussed is GPC2; the disease is prostate cancer.